Key result
Real-world inclisiran therapy is associated with a ~49% drop in LDL-C for secondary prevention.
Why the study?
Does the addition of inclisiran to standard lipid therapy reduce LDL-C and improve compliance with European lipid targets in secondary prevention patients?
Observational (n=55)
No
Does the addition of inclisiran to standard lipid therapy reduce LDL-C and improve compliance with European lipid targets in secondary prevention patients?
Answers are grounded in this paper and cite their sources.
In a real-world secondary prevention setting, adding inclisiran to maximally tolerated lipid therapy reduces LDL-C by nearly 50% and helps over 40% of patients achieve ESC targets.
Background Inclisiran is a small interfering RNA (siRNA) that interferes with the production of proprotein convertase subtilisin kexin type 9 (PCSK9). This results in the lowering of circulating low-density lipoprotein cholesterol (LDL-C). In clinical trials inclisiran showed effective lowering of LDL-C reduction of ± 50 %. Purpose We sought to analyse the data from the first 55 patients to be initiated on inclisiran in a cardiology secondary prevention clinic to establish whether this addition to standard lipid therapy could improve compliance with European lipid targets. Methods We collected and analysed data on every patient who was initiated on inclisiran in the clinic during a period of 16 months from March 2024. Baseline lipid profiles were taken prior to initiation to ensure criteria was met and further profiles requested at 3 months and 5 months. A target level of LDL-C <1.4mmol/L was used as defined by the European Society of Cardiology (ESC) 2021 guidelines. Results At 16 months there was an average decrease in total cholesterol levels of 33%, non-HDL-C levels of 44% and LDL-C levels of 49%, with 41% of patients now meeting lipid targets for LDL-C as defined by ESC. Conclusion In a real-world setting, the addition of inclisiran to maximally tolerated lipid therapy can significantly reduce LDL-C levels and improve compliance with lipid targets when used in line with ESC guidelines.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2026) conducted an observational in Hyperlipidemia in secondary prevention (n=55). Inclisiran vs. Baseline was evaluated on Decrease in LDL-C levels. In a real-world secondary prevention setting, inclisiran therapy resulted in an average 49% decrease in LDL-C levels, enabling 41% of patients to meet ESC lipid targets.
Synapse has enriched 10 related papers. Consider them for comparative context: